A phase I study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer.

被引：2
|
作者：
Beatty, G. L.
Chiorean, E. G.
Torigian, D. A.
Teitelbaum, U. R.
Sun, W.
Fly, K. D.
Huhn, R. D.
Vonderheide, R. H.
O'Dwyer, P. J.
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[3] Univ Penn, Philadelphia, PA 19104 USA
[4] Pfizer Inc, New London, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.2539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2539
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I/Ib study of enzalutamide and gemcitabine and cisplatin in bladder cancer.
    Gupta, Shilpa
    Fishman, Mayer N.
    Dhillon, Jasreman
    Magliocco, Anthony Martin
    Puskas, John
    Caceres, Gisela
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [42] Phase II study of gemcitabine, capecitabine and cisplatin in patients with advanced pancreatic cancer.
    Chang, HM
    Kim, TW
    Ahn, JH
    Ryu, MH
    Lee, JS
    Kim, WK
    Kang, YK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 368S - 368S
  • [43] Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
    Du, Kun
    Huang, He
    TRANSLATIONAL ONCOLOGY, 2025, 52
  • [44] A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
    Shan, Yan-Shen
    Li, Chung-Pin
    Khan, Gazala
    Lee, Woo Jin
    Choi, Hye Jin
    Chang, Heung-Moon
    Lee, Moon Hee
    Wallmark, John M.
    Chen, Pei-Ni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 648 - 648
  • [45] A phase I study of oxaliplatin, full-dose gemcitabine and concurrent radiation therapy in patients with pancreatic cancer.
    Desai, S. P.
    Ben-Josef, E.
    Lawrence, T. J.
    Francis, I. R.
    Greenson, J. K.
    Alfred, C. E.
    Colletti, L. M.
    Simeone, D. M.
    Normolle, D. P.
    Zalupski, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 204S - 204S
  • [46] Intra-tumoral CD40 antibody with irreversible electroporation (IRE) in locally advanced pancreas cancer.
    White, Rebekah Ruth
    Berman, Zachary
    Wainberg, Zev A.
    Miller, Aaron
    Messer, Karen
    Ambarkhane, Sumeet Vijay
    Schoenberger, Stephen Philip
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS787 - TPS787
  • [47] A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers
    Ko, Andrew H.
    Chao, Joseph
    Noel, Marcus S.
    Shankaran, Veena
    Sohal, Davendra
    Crow, Mary
    Oberstein, Paul E.
    Scott, Aaron J.
    McRee, Autumn J.
    Rocha Lima, Caio Max Sao Pedro
    Fong, Lawrence
    Keenan, Bridget P.
    Soto, Maira
    Filbert, Erin L.
    Hsu, Frank J.
    Yang, Xiaodong
    CANCER RESEARCH COMMUNICATIONS, 2025, 5 (02): : 349 - 357
  • [48] A combined effect of immune checkpoint inhibitors and a CD40 agonistic antibody in a pancreatic cancer mouse model
    Ichikawa, Juri
    Kawano, Kuniyuki
    Kato, Shingo
    Kurotaki, Daisuke
    Kuroishikawa, Ryo
    Kawase, Wataru
    Yoshida, Haruka
    Hiroshima, Yukihiko
    Endo, Itaru
    Maeda, Shin
    Nakajima, Atsushi
    Tamura, Tomohiko
    CANCER SCIENCE, 2024, 115 : 763 - 763
  • [49] Balancing efficacy and toxicity of a fibroblast activation protein dependent tetravalent CD40 agonist antibody for cancer therapy
    Chen, Simeng
    Lin, Yuan
    Zhou, Xiaoru
    Sun, Xing
    Yang, Changyong
    Liao, Cheng
    CANCER RESEARCH, 2024, 84 (06)
  • [50] A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer.
    Kortmansky, JS
    O'Reilly, EM
    Minsky, BD
    Puleio, SA
    Winkelmann, J
    Kelsen, DP
    Schwartz, GK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
12345